GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (OTCPK:CHMMF) » Definitions » Scaled Net Operating Assets

CHMMF (Chimeric Therapeutics) Scaled Net Operating Assets : 0.46 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Chimeric Therapeutics's operating assets for the quarter that ended in Dec. 2023 was $15.50 Mil. Chimeric Therapeutics's operating liabilities for the quarter that ended in Dec. 2023 was $8.58 Mil. Chimeric Therapeutics's Total Assets for the quarter that ended in Jun. 2023 was $15.02 Mil. Therefore, Chimeric Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.46.

Chimeric Therapeutics Scaled Net Operating Assets Historical Data

The historical data trend for Chimeric Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Scaled Net Operating Assets Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Scaled Net Operating Assets
0.08 0.18 0.09 0.13

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Scaled Net Operating Assets Get a 7-Day Free Trial 0.26 0.34 0.15 0.46 0.11

Competitive Comparison of Chimeric Therapeutics's Scaled Net Operating Assets

For the Biotechnology subindustry, Chimeric Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimeric Therapeutics's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's Scaled Net Operating Assets falls into.


Chimeric Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Chimeric Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Jun. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Jun. 2024 )
=(Operating Assets (A: Jun. 2024 )-Operating Liabilities (A: Jun. 2024 ))/Total Assets (A: Jun. 2023 )
=(8.114-6.115)/15.017
=0.13

where

Operating Assets(A: Jun. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=10.141 - 2.027
=8.114

Operating Liabilities(A: Jun. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=8.501 - 0 - 2.386
=6.115

Chimeric Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2023 )
=(Operating Assets (Q: Dec. 2023 )-Operating Liabilities (Q: Dec. 2023 ))/Total Assets (Q: Jun. 2023 )
=(15.504-8.584)/15.017
=0.46

where

Operating Assets(Q: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=17.863 - 2.359
=15.504

Operating Liabilities(Q: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=8.584 - 0 - 0
=8.584

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chimeric Therapeutics Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (OTCPK:CHMMF) » Definitions » Scaled Net Operating Assets
Comparable Companies
ASX:TRP ASX:VBS ASX:IMC ASX:PAB ASX:ATX ASX:KZA ASX:ATH ASX:IXC ASX:BGT ASX:ACR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
CHM:Australia
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Website
https://www.chimerictherapeutics.com
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics Headlines

From GuruFocus

Chimeric Therapeutics Ltd at NWR Communications Virtual Conference Transcript

By GuruFocus Research • 02-13-2024

Chimeric Therapeutics Ltd Investor Webinar Transcript

By GuruFocus Research • 02-13-2024

Chimeric Therapeutics Ltd FNN Investor Event Transcript

By GuruFocus Research • 02-13-2024